Linzess (linaclotide), a medication for irritable bowel syndrome (IBS) with constipation or chronic idiopathic constipation is now available in American pharmacies, Ironwood Pharmaceuticals Inc. and ...

Allergan and Ironwood are going where GI commercials have not gone before: into the bathroom. A new TV ad for Linzess, begun last week, features two different people sitting on the toilet—viewers see ...

There’s a new competitor to Allergan and Ironwood’s Linzess on the block in the chronic idiopathic constipation (CIC) market. And the way some industry watchers see it, it may not be long before the ...

Credit: Shutterstock. Linzess is a guanylate cyclase-C agonist. The Food and Drug Administration (FDA) has approved Linzess ® (linaclotide) for the treatment of functional constipation (FC) in ...

A long time ago in a galaxy far, far away, an IBS drug called Zelnorm was launched. Unique in the universe, Zelnorm’s DTC campaign famously used words and images drawn on naked tummies. Although that ...

Medicare Part D plans typically cover Linzess. Many beneficiaries have out-of-pocket costs between $0 and $50, though this can vary based on the specific plan and location. The Extra Help program is ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

Findings showed 30% of patients taking linaclotide 145mcg achieved the primary endpoint of combined responder. The Food and Drug Administration (FDA) has approved Linzess ® (linaclotide) for the ...

Ironwood Pharmaceuticals, Inc. IRWD reported fourth-quarter 2020 adjusted earnings of 36 cents per share, which beat the Zacks Consensus Estimate of 27 cents. The company had reported adjusted ...